‘At-risk’ policy change: Govt puts money on new-platform Covid-19 vaccine

‘At-risk’ policy change: Govt puts money on new-platform Covid-19 vaccine

Newsdesk |
June 4, 2021

The decision to book 30 crore doses of Biological E’s Covid-19 vaccine before it has launched marks a major shift in the government’s stance on procurement for mass immunisation against the coronavirus.

New Delhi, 4 June 2021

As per news report of The Indian Express, the advance order, which includes Rs 1,500 crore in monetary assistance to help the company stockpile doses, is the government’s first at-risk investment on vaccines so far. It is significant that the government has put its money on a novel platform for a Covid-19 vaccine that is yet to receive regulatory approval. Bio E’s two-dose vaccine, known as Corbevax, is likely to be among the cheapest Covid-19 vaccines that will be available in India; it is also expected that it will be easy to scale up production. Corbevax uses a recombinant protein platform, which is not used by any other vaccine in India currently.

Source -indianexpress.com


If you like the story and if you wish more such stories, support our effort Make a donation.


If you believe investigative journalism is essential to making democracy functional and accountable support us. »